Dr. Joseph M. Tuscano
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
22 reported clinical trials
45 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
13q positive
13q negative
2Non-Hodgkin's Lymphoma
CD20 positive
CD30 positive
CD20
Affiliated Hospitals
Clinical Trials Joseph M. Tuscano is currently running
Epcoritamab + Chemotherapy
for Diffuse Large B-Cell Lymphoma
This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide \[RICE\], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X\] or gemcitabine and oxaliplatin \[Gem/Ox\]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP/X and Gem/Ox, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.
Recruiting1 award Phase 28 criteria
Triple Drug Therapy
for Follicular Lymphoma
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
Recruiting1 award Phase 210 criteria
More about Joseph M. Tuscano
Clinical Trial Related1 year of experience running clinical trials · Led 22 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Joseph M. Tuscano has experience with
- Obinutuzumab
- Lenalidomide
- Rituximab
- Venetoclax
- Ibrutinib
- Brentuximab Vedotin
Breakdown of trials Joseph M. Tuscano has run
Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph M. Tuscano specialize in?
Joseph M. Tuscano focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are 13q positive.
Is Joseph M. Tuscano currently recruiting for clinical trials?
Yes, Joseph M. Tuscano is currently recruiting for 11 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Joseph M. Tuscano has studied deeply?
Yes, Joseph M. Tuscano has studied treatments such as Obinutuzumab, Lenalidomide, Rituximab.
What is the best way to schedule an appointment with Joseph M. Tuscano?
Apply for one of the trials that Joseph M. Tuscano is conducting.
What is the office address of Joseph M. Tuscano?
The office of Joseph M. Tuscano is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.